Company news

BioCardia, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

September 4, 2023

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

August 8, 2023

BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023

August 1, 2023

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

July 23, 2023

BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency

July 4, 2023

BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study

June 19, 2023

BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan

June 7, 2023

BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

May 22, 2023

BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

May 9, 2023

BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

May 8, 2023

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

May 2, 2023

BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

April 27, 2023

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

April 3, 2023

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

March 28, 2023

BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

March 15, 2023

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

March 5, 2023

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

January 31, 2023

BioCardia Letter to Shareholders

December 21, 2022

BioCardia Announces $3.6 Million Private Placement of Common Stock

December 14, 2022

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

December 5, 2022

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

November 8, 2022

BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

November 1, 2022

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

October 2, 2022

BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

September 8, 2022

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

August 30, 2022

BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure

August 23, 2022

BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results

August 9, 2022

BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

August 3, 2022

BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial

July 31, 2022

BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies

June 14, 2022

BioCardia Reports First Quarter 2022 Business Highlights and Financial Results

May 10, 2022

BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

May 3, 2022

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

April 11, 2022

BioCardia Reports 2021 Financial Results and Recent Business Highlights

March 28, 2022

BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure

March 21, 2022

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

February 28, 2022

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

February 13, 2022

BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure

February 2, 2022

BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference

January 9, 2022

BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates

December 14, 2021

BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights

November 9, 2021

BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021

November 7, 2021

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

October 20, 2021

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies

October 11, 2021

BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial

October 6, 2021

BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)

October 5, 2021

BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)

September 8, 2021

BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights

August 11, 2021

BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies

July 14, 2021

BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

June 22, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.